***Word counts:***

*Word count: 3196*

*Abstract word count: 300*

***Title:*** *On the Role of Artificial Intelligence in Medical Imaging of COVID-19*

***Running Title:*** *On the Role of AI in Medical Imaging of COVID-19*

*Jannis Born[1,2,*], David Beymer[3,*], Deepta Rajan[3], Adam Coy[3,4], Vandana V. Mukherjee[3], Matteo Manica[1], Prasanth Prasanna[5,3], Deddeh Ballah[6,3], Michal Guindy[7,8], Dorith Shaham[9], Pallav L. Shah[10,11,12], Emmanouil Karteris[13], Jan L. Robertus[12], Maria Gabrani[1], Michal Rosen-Zvi[14,15]*

[1]*IBM Research Europe, Zurich, Switzerland*

[2]*Department for Biosystems Science & Engineering, ETH Zurich, Switzerland*

[3]*IBM Almaden Research Center, CA, USA*

[4]*Vision Radiology, Dallas, TX, USA*

[5]*Department of Radiology and Imaging Sciences, University of Utah Health Sciences Center, Salt Lake City, Utah*

[6]*Department of Radiology, Seton Medical Center, Daly City, CA, USA*

[7]*Assuta medical Centres Radiology, Tel-Aviv, Israel*

[8]*Ben-Gurion University Medical School, Israel*

[9]*Department of Radiology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel*

[10]*Royal Brompton Hospital, Imperial College, London, UK*

[11]*Chelsea & Westminster Hospital, London, UK*

[12]*National Heart & Lung Institute, Imperial College London, UK*

[13]*College of Health, Medicine and Life Sciences, Brunel University London, UK*

[14]*IBM Research Haifa, Israel*

[15]*Faculty of Medicine, The Hebrew University of Jerusalem, Israel*

* *Corresponding authors:* jab@zurich.ibm.com, *beymer@us.ibm.com*

**Keywords:** Artificial Intelligence; Meta Review; COVID-19; Coronavirus; Chest X-ray; Chest CT; Chest Ultrasound; Machine Learning

**Author's contributions:** MRZ, DB, JLR, EK and MGA conceived the presented work. MRZ conceived the meta-analysis and supervised this project, and MRZ and MGA set the high-level objectives of this work. JB and MM developed the software to perform paper keyword searches. JB, DM, DR, AC, VM, EK and MGA manually reviewed papers. JB analyzed the results and JB and DR created the figures. All authors contributed toward the interpretation and improvement of the analysis. DB and JB led and distributed the manuscript writing efforts. JB, DB, AC, DR, MGA, EK, DS, PS, MGU and MRZ wrote full, individual sections of the manuscript. All authors reviewed initial versions and contributed significantly to the different sections of the manuscript and approved the submitted version.

**Funding Information:** None.

**Disclosures:** No author has a conflict of interests.

**Abbreviations:** ACR (American College of Radiology), AI (Artificial Intelligence), CT (Computed Tomography), CXR (Chest Radiographs), DL (Deep Learning), US (Ultrasound), LUS (Lung Ultrasound), MI (Medical Imaging), PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses), RT-PCR (Reverse Transcriptase Polymerase Chain reaction)

**Data and code availability:** The source code used for the publication keyword search is available via https://pypi.org/project/paperscraper/. A file with the detailed results of the publication meta-analysis is enclosed as Supplementary Material (online only).

# Abstract

**Purpose**

The global COVID-19 pandemic has accelerated the development of numerous digital technologies in medicine from telemedicine to remote monitoring. Concurrently, the pandemic has resulted in huge pressures on healthcare systems. Medical imaging from chest radiographs to computed tomography and ultrasound of the thorax have played an important role in the diagnosis and management of the coronavirus infection.

**Methods**

We undertook a systematic review of the literature focused on MI in COVID-19 and the utility of AI. Keyword searches were performed on PubMed and preprint servers including arXiv, bioRxiv and medRxiv; 338 papers were included in a meta-analysis and manually reviewed to assess solutions in AI according to their clinical relevance. The maturity of the papers was evaluated based on four criteria: peer-review, patient dataset size, algorithmic complexity and usage of the AI in clinical practice.

**Results**

In the first three quarters of 2020, we identified 3444 papers on MI in COVID-19, of which 556 had at least some focus on AI. 2039 of 3444 were specific to imaging modalities and predominantly (80.7%) focused on CT (9.9% on LUS and 9.5% on CXR). The AI literature was predominantly focused on CXR (51.2%), 36.1% on CT and 1.8% on LUS. Only a small portion of the papers were judged as mature (3.8%) and most AI papers focused on disease detection (72.8%).

**Conclusions**

This review evidences a disparity between clinicians and the AI community, both in the focus on imaging modalities and performed tasks. Better collaboration is needed to allocate resources optimally for the development of clinically relevant solutions that are validated on large-scale patient data.

**Clinical implications**

AI may aid clinicians and radiologists by providing better tools for localization and quantification of disease features and changes thereof, and, with integration of clinical data, may provide better diagnostic performance and prognostic value.

# Introduction

The COVID-19 pandemic has created a desperate need for fast, ubiquitous, accurate, and low-cost tests, and lung imaging is a key complementary tool in the diagnosis and management of COVID-19[1,2]. According to the ACR and the Fleischner Society Consensus Statement, imaging of COVID-19 is indicated in case of worsening respiratory symptoms, and, in a resource-constrained environment, for triage of patients with moderate-to-severe clinical features and a high probability of disease[3,4]. This involves two main tasks. The first is diagnosis, including incidental diagnosis and providing supporting evidence in clinical situations in which a false negative RT-PCR test is suspected. The second task is to help evaluate treatment outcomes, disease progression and anticipated prognosis. The field of AI in MI is flourishing in the context of COVID-19[5,6,7], and hopes are high that AI can support clinicians and radiologists on these tasks. In this paper, we review the current progress in the development of AI technologies for MI to assist in addressing the COVID-19 pandemic, discuss how AI meets the identified gaps and share observations regarding the maturity and clinical relevancy of these developments.

# Methods

To discover trends from the overwhelming research activities in COVID-19, AI and MI, a systematic review and meta-analysis were performed according to the PRISMA guidelines[8]. Literature, indexed

in PubMed and three preprint servers, namely, arXiv, bioRxiv and medRxiv, were queried. The process is illustrated in Figure 1 and shows two main streams of queries; a broad one using “AI” AND “COVID-19” AND “Medical Imaging” and a modality-specific one with “AI” AND “COVID-19” AND “Lung” AND (“CT” OR “CXR” OR “US”). Following PRISMA guidelines, combining the results of both queries across all databases led to the identification of 338 papers about AI on lung imaging for COVID-19. These papers were included in a manual meta-analysis to review the maturity of the AI technologies and the trends in the rapidly evolving field (for the detailed procedure and a list of synonyms used see appendix Table A1). Publications of AI technology typically tend to report a proof of concept, an illustration of a success in a non-clinical setting, or a report of clinically successful experiments. Many of the papers identified are not published in peer reviewed journals. To further evaluate the maturity of papers, we included the size of patient data used for training and evaluation, the deployment and adoption of solutions in hospitals, and the complexity of the AI framework. We also distinguished the type of data used between internally collected and publicly available databases. Moreover, we manually selected the most AI-related common tasks addressed in the papers, such as detection, segmentation, characterization and outcome prediction, and mapped them into three main clinically relevant categories: diagnosis, severity assessement and prognosis, and one technical task: segmentation. The task segmentation describes papers that focused on mere localization of lung tissue or other disease features without the application of any directly clincially relevant downstream tasks.

For publications that focused on several categories, the major task was chosen. For example, a number of publications classified as “diagnosis” or “severity assessment” utilized segmentation methods on the fly. Papers that provided a review of existing technologies and did not introduce original new technoglogy were labeled as “review”. The remaining evaluation criteria per publication were imaging modality, country of authors and country of data source. For each paper, we also recorded the total number of citations indicated on Google Scholar as of 8.11.2020 and converted it to the monthly citation rate. The meta-analysis was blindfolded to the number of citations.

# Results

## Progress in AI for Medical Imaging

In recent years, AI solutions have shown to be capable of assisting radiologists and clinicians in detecting disease, assessing severity, automatically localizing and quantifying disease features or providing an automated assessment of disease prognosis[9]. AI for MI has received extraordinary attention in 2020 and witnessed a multitude of interdisciplinary projects attempting to blend AI technologies with knowledge from MI in order to combat COVID-19. A keyword search combining AI and MI revealed 2563 papers in 2019, while the first three quarters of 2020 have seen already 3597 such papers (Figure 2). Out of these publications, 556 are related to COVID-19, indicating that COVID-19 has accelerated the development of AI in MI.

A pioneer in the progress of AI for MI is the tremendous success in using AI for detection of breast cancer in screening mammography, a success reported by multiple research groups and achieved after 10 years of effort. These achievements were enabled by large-scale data collections coming from diverse countries such as US, UK, Sweden, South Korea and Israel, see e.g.[10,11] and references therein. Similarly, before the oubreak of the COVID-19 pandemic, significant progress has been made in diagnosing lung conditions using CXR and CT, driven by access to open source datasets and labels. An example is the cutting edge result of the DL-based approach that outperforms radiologists in detecting several pulmonary conditions on CX[12]. Recently, technologies aiming to assist radiologists in such tasks have been made available in the market[13].

## Publication Keyword Search

To enable a perspective on the emergence of AI for MI of COVID-19, we have compiled a comparison on the progress of automatic analysis in breast and lung imaging, in the literature defined above, from January 1st 2017 to Septemeber 30th 2020. Figure 3(left) shows a stable growth of papers in AI on both lung and breast imaging over the years 2017-2019. In 2020, the rise of lung-related papers has been accelerated by COVID-19, causing an additional ~200 papers (111% growth rate) only in the first half of 2020.

**Preprint vs peer-reviewed papers:**

To compare the impact of individual modalities, Figure 3(right) shows that 2019 witnessed a stable trend of ~100 papers per quarter on AI with shares of 72% for CT, 25% for CXR and 2% for LUS. After the COVID-19 outbreak, numbers soared to 138, 340 and 365 papers for Q1-Q3 2020 respectively. This rise was spontaneously evoked by COVID-19, as excluding papers mentioning COVID-19 would have resulted in a continuation of the stable trend (see lightly shaded bars) of a hypothetical 100-150 publications. Indicating a shift in the focus of research, the first three quarters of 2020 produced more papers for each modality than all of 2019. Note that, for non-COVID-19 papers, the ratio between preprints and PubMed indexed papers for AI in breast and chest is 30% and 46%, respectively; for COVID-19 related papers, this ratio rises to 73%.

## Meta-analysis

By focusing on CT, CXR and US, we quantified the publication efforts of AI for MI of COVID-19 and identified 338 papers which were included in a manual meta-analysis to review the maturity of the AI technologies and the trends in the rapidly evolving field.

**Disparity between Clinical and AI Communities:** Of the 3444 papers about MI and COVID-19 (see Figure 2(right)), 2039 are specific to modalities as shown in Figure 4(left), indicating a dominance of CT in clinical papers (80.7%) and a roughly even proportion of LUS (9.9%) and CXR

imaging (9.5%). By using publication counts as an indirect indicator on scientific response, we observe a mismatch in the focus of the AI community in comparison to the clinical community as illustrated by the distribution of papers per modality in Figure 4(right) that shows a clear dominance of CXR (51%) across AI papers.

In addition, the vast majority (73%) of papers focused on diagnosis of COVID-19 over tasks like severity and prognosis (Figure 5(left)). This trend is in contrast to the ACR guidelines appraising imaging as an inconclusive test for COVID-19 detection. Note that a key concern was the unanimous use of only one imaging modality data for training the algorithms (51% CXR, see Figure 4(right)). While 11% of papers exploited multimodal imaging data towards building their AI models, studies on multimodal imaging data of the same patient cohort are lacking with one exception[14].

**Most AI Solutions for COVID-19 have Low Maturity:** The maturity of the papers was assessed by co-authors who have developed or worked with DL algorithms (see Figure 5(middle)). Only 13 highly mature studies were identified[15,16,17,18,19,20,21,22,23,24,25,26,27]. The list of papers and their task and modality appear in Table 1. For details on the task and maturity as distributed by modality see appendix (Fig. A1). Posteriori, we found that the monthly citation rate was significantly higher for high than for low maturity papers (4.1 vs. 2.2, $p<0.05$, U), while the correlation was insignificant ($r=0.08$) across all three maturity levels. However, the correlation of monthly citation rate was highly correlated ($r=0.32$, $p<1e-9$) with months elapsed since publication. This suggests that absolute citations and relative citation rates are insufficient quality measures and we instead observe a tendency toward continuous citation of publications that appeared early in the pandemic.

**Overuse of Small Incomprehensive Public Datasets:** We observed that only 28% of papers used proprietary or clinical data (Figure 5(right)), while almost 67% analysed publicly available databases. Such databases exist for CT[28], CXR[29] and LUS[30] and are usually assembled by AI researchers,

contain data fetched from publications and are comprised of no more than a few hundred images from heterogenous sources/devices without detailed patient information. Accordingly, the geographical diversity of data sources was not very high (23 countries), and data donators were mostly countries hit early from the pandemic, i.e. China (51%) and, to a lesser extent, USA (13%) and Italy (12%). First-authors from 44 countries and 6 continents contributed to the research, evidencing a global collaborative spirit.

**Diagnosis:** 73% of the papers focused on COVID-19 detection and 8 out of the 13 mature papers (62%) are addressing this task. However, the most prominent COVID-19 test relies on the identification of viral RNA using RT-PCR[31]. Serological tests identifying antibodies are also used[32], but as antibody development can take up to 5 days in humans, they are inappropriate for detection of early infections[33]. Compared to diagnostic tests, CT imaging may be more sensitive at a single time point for the diagnosis of COVID-19[34]. The first main diagnostic challenge is the non-specificity of COVID-19 patterns and their differentiation from non-COVID-19 viral pneumonia[35]. Here, non-imaging assessments like anamnesis (e.g. contact with a confirmed COVID-19 patient or more specific symptoms such as olfactory loss) could contribute to the diagnosis. Secondly, asymptomatic patients with unaffected lungs are notoriously challenging to be detected. In both cases, however the lack of visibly distinguishing features for COVID-19 might not imply a limited ability of DL-based approaches, which might still be able to automatically identify (segment) distinguishing features as part of training[36]. If DL approaches combine CT and clinical features, the performance of radiologists in the detection of symptomatic COVID-19 patients can be matched, and, crucially, asymptomatic patients with normal CT scans were demonstrated to be identified in 68% of the cases[15]. In another study, AI recovered full-dose CT from ultra-low-dose CTs with a satisfying acceptance score of 4.4 out of 5 by radiologists (compared to 4.7 and 2.8 for full- and ultra-low-dose respectively) and thus helped to reduce the CT radiation dose by up to 89% while still facilitating downstream diagnosis[37]. The only highly mature diagnostic study using CXR included almost 6000 scans from >2000 COVID-

19 patients and their DL model exceeded the diagnostic performance of thoracic radiologists as found by significantly higher area under the curve of 0.94 (vs. 0.85) and sensitivities when matching specificity to radiologists' performance[38].

**Severity Assessment:** Early in the pandemic, chest CT was used to identify radiological manifestations[39]. Indeed, imaging findings of COVID-19 patients have been shown to correlate with disease severity[40] and CT scanning accurately assessed the severity of COVID-19 and helped monitor disease transformation among different clinical conditions[41]. A retrospective comparison of imaging findings on chest CTs with disease severity revealed an increased occurrence of consolidation, linear opacities, crazy-paving pattern and bronchial wall thickening in severe patients at a higher frequency than in non-severe COVID-19 patients. The CT findings correlated with several worse symptoms, including a respiratory rate greater than 30 breaths per minute, and oxygen saturation of 93% or less in a resting state among other phenotypes[39]. In clinical practice, often progress assessments as well as patient management is performed based on CXR and not chest CT. AI that provides assessment of severity could be useful if it was quantifiable and accurate and 4 publications were found mature in performing this task[23,24,25,26]. One of them utilized a dataset of multiple CT scans per patients and introduced a "CT scan simulator" that modelled the temporal evolution of the CT through disease progression and was evaluated on multi-national and multi-machine data[25]. The work moreover proposed to decompose the task of CT segmentation from one 3D into three 2D problems, thus achieving remarkable performance. Others developed a clinically useful AI tool for quantification of pulmonary opacity within 10 days and achieved human-level performance when training on less than 200 CT scans[23]. Notably, despite the overall overhead of CXR compared to CT in the analysed publications, only 4 publications in the meta-analysis focused on severity assessment based on CXR (20 on CT, 1 on LUS). One of them was found mature – and trained DL models on lung segmentation and opacity detection of 48 COVID-19 patients and achieved an agreement measure (Cohen's kappa) of 0.51 for alveolar opacities and 0.71 for interstitial opacities[26]. In the only identified publication

with multimodal imaging data for one patient cohort[14], manual airspace disease segmentation of CTs in 86 COVID-19 patients was used as ground truth to train an AI on volumetric quantification from CXR. The obtained correlation percentage of opacity (PO) volume (CT) and PO area (CXR) was ~0.8 for both AI and averaged human experts.

**Prognosis:** Very few of the papers (15, i.e. 4%) focused on AI of lung MI to assess prognosis of COVID-19. This reflects the overall gap in knowledge of the long-term effects of COVID-19 and the lack of historical data to enable training on large scale prognosis data. Moreover, in the past few months the hyper-inflammatory response induced by COVID-19 has been identified as a major cause of disease severity and death[42]. Studies have focused in the identification of predictive biomarkers of pathogenic inflammation. Lung imaging is not expected to reflect these biomarkers' expression, leading to limited prognosis accuracy based on imaging. One study we found highly mature seamlessly integrated a diagnostic module (based on a CT lung-lesion segmentation) with a prognostic module that combined clinical metadata and quantification of lung-lesion features[27]. The system demonstrated performance comparable to a senior radiologist (sensitivity 93%, specificity 90%), aided junior radiologists to improve their performance to the senior level and was developed on a multi-center database with 3,777 patients. The prognostic module predicted progression to critical illness and could evaluate drug treatment efficacy by three drugs. Notably, the entire dataset as well as the source code is available to the public to support the development of a better system and to validate their study.

**Segmentation:** The main abnormalities observed in common and severe COVID-19 cases respectively were ground glass opacities (GGOs) and patchy consolidation surrounded by GGOs. COVID-19 pneumonia manifests with chest CT imaging abnormalities, even in asymptomatic patients, with rapid evolution from focal unilateral to diffuse bilateral GGOs that progress to or co-exist with consolidations within 1–3 weeks[43]. The visual features of GGOs and consolidation lend

themselves to image analysis by DL networks, and with 27 publications (8%) segmentation was the second-most performed task after diagnosis. In our analysis none of the mature papers focused on providing a pure segmentation on lung images, but rather used segmentation to enable other clinical tasks, such as diagnosis, as discussed above. In most cases (81%) segmentation publications utilized external data sources with little or no clinical collaboration. Some segmentation-based models output pixelwise-labelled tissue maps of GGO or consolidation regions, providing quantitative localization of findings and identification of disease features, which can be especially informative in clinical tasks such as grading disease severity or tracking progression over time. This can be achieved by segmenting anatomical landmarks with reinforcement learning and computing percentage of opacity and lung severity score as complementary severity measures[44].

In an exhaustive empirical evaluation of DL models on a clinical dataset of almost 100 COVID-19 patients, distinguishing lesion types was found more difficult than lung segmentation or binary lesion segmentation and model ensembles were found best performance[45]. The manual delineation of radiologists necessary for segmentation tasks inherently introduces some inter-rater variability which necessitates segmentation techniques that can deal with uncertainty in annotations [46]. Others have proposed topological modelling techniques that explore structural relationships between vessels, airways and the pleural wall and break up with the common strategy of utilizing fully local modules such as convolutions[47].

# Discussion

An ideal imaging modality should be safe, ubiquitous, accurate, fast, and preferably provide high-quality reproducible results via portable devices. The three different imaging modalities addressed in here differ in their clinical use, their availability, portability, safety and reproducibility. CT is restricted to modern medical facilities[48]. CXR is notoriously less sensitive than CT[49], yet, it is the most abundantly used modality across the globe when managing COVID-19 patients. The practical

advantages of LUS include non-invasiveness and portability and its consequent role in triage[50]. However, LUS is operator dependent and requires close patient contact for a relatively longer time[51]. It was described as a preferred modality in Italy[52] during spring 2020, but it is not used as extensively in other geographies, mainly applied for patients with CT/CXR contraindications (children, pregnant women) and predestined to study solid organs unlike the lung. Some reported higher sensitivity than CXR in COVID-19 diagnosis[53], or even comparable diagnostic accuracy to CT[54,55], but the role of LUS for the COVID-19 pandemic is still actively debated in the literature[56,57,58]. A summary of the differences between the imaging modalities is provided in Table 2.

The number of papers on AI in MI for COVID-19 have grown exponentially in the past three quarters, and the quality of the manuscripts varies significantly. The AI literature has focused mostly on CXR and CT, similar to prevalence in clinical practice, whereas LUS has received little attention from AI researchers. AI literature focus mainly on diagnosis with less coverage on other tasks with higher clinical relevance, such as severity assessment and monitoring. With few exceptions, the authors of the best publications did not release their clinical datasets, raising concerns about reproducibility and transparency of their studies as was recently exemplified for *Nature* study on breast cancer screening[59,60] and a COVID-19 mortality prediction study[61] that was found irreproducible by three independent research groups from different countries[62,63,64]. Given the global, unprecedented public health challenge caused by COVID-19, we strongly encourage medical researchers to follow the trends toward open-source development in other fields and expedite a transformation toward a common practice of publishing data and code. We hope that a better collaboration between the AI community and medical experts leads to more mature and conducive technologies that will assist clinicians and radiologists in addressing pressing clinical decision support needs.

# References


[1] D. Dong *et al.*, "The role of imaging in the detection and management of COVID-19: a review," *IEEE Rev. Biomed. Eng.*, 2020.
[2] G. Pascarella *et al.*, "COVID-19 diagnosis and management: a comprehensive review," *J. Intern. Med.*, vol. 288, no. 2, pp. 192–206, Aug. 2020.
[3] Rubin, G.D., Ryerson, C.J., Haramati, L.B., Sverzellati, N., Kanne, J.P., Raoof, S., Schluger, N.W., Volpi, A., Yim, J.J., Martin, I.B. and Anderson, D.J., 2020. The role of chest imaging in patient management during the COVID-19 pandemic: a multinational consensus statement from the Fleischner Society. *Chest*.
[4] American College of Radiology, 2020. ACR recommendations for the use of chest radiography and computed tomography (CT) for suspected COVID-19 infection. ACR website. Advocacy-and Economics/ACR-Position-Statements/Recommendations-for-Chest-Radiography-and-CTfor-Suspected-COVID19-Infection. Updated March, 22.
[5] P. Lomoro *et al.*, "COVID-19 pneumonia manifestations at the admission on chest ultrasound, radiographs, and CT: single-center study and comprehensive radiologic literature review," *European journal of radiology open,* 2020.
[6] D. Shi, Feng and Wang, Jun and Shi, Jun and Wu, Ziyan and Wang, Qian and Tang, Zhenyu and He, Kelei and Shi, Yinghuan and Shen, "Review of artificial intelligence techniques in imaging data acquisition, segmentation and diagnosis for covid-19," *IEEE Rev. Biomed. Eng.*, 2020
[7] L. Wynants *et al.*, "Prediction models for diagnosis and prognosis of covid-19: Systematic review and critical appraisal," *BMJ*, vol. 369, p. 18, Apr. 20 .
[8] Moher, David, et al. "Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement." *PLoS med* 6.7 (2009): e1000097.
[9] X. Liu *et al.*, "A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: a systematic review and meta-analysis," *Lancet Digit. Heal.*, vol. 1, no. 6, pp. e271–e297, Oct. 2019.
[10] H. E. Kim *et al.*, "Changes in cancer detection and false-positive recall in mammography using artificial intelligence: a retrospective, multireader study," *Lancet Digit. Heal.*, vol. 2, no. 3, pp. e138–e148, Mar. 2020.
[11] M. Chorev, et al, "The Case of Missed Cancers: Applying AI as a Radiologist's Safety Net." International Conference on Medical Image Computing and Computer-Assisted Intervention (pp. 220-229). Springer, Cham. 2020.
[12] J. Irvin *et al.*, "CheXpert: A Large Chest Radiograph Dataset with Uncertainty Labels and Expert Comparison," *Proc. AAAI Conf. Artif. Intell.*, vol. 33, no. 01, pp. 590–597, Jul. 2019.
[13] Saba, L., Biswas, M., Kuppili, V., Godia, E.C., Suri, H.S., Edla, D.R., Omerzu, T., Laird, J.R., Khanna, N.N., Mavrogeni, S. and Protogerou, A., 2019. The present and future of deep learning in radiology. European journal of radiology, 114, pp.14-24.
[14] Barbosa Jr, Eduardo Mortani, et al. "Automated detection and quantification of COVID-19 airspace disease on chest radiographs: A novel approach achieving radiologist-level performance using a CNN trained on digital reconstructed radiographs (DRRs) from CT-based ground-truth." arXiv preprint arXiv:2008.06330 (2020).
[15] Mei, X., Lee, H.-C., Diao, K.-Y., Huang, M., Lin, B., Liu, C., et al. Artificial intelligence-enabled rapid diagnosis of patients with COVID-19. *Nature Medicine*. 2020; 26(8), 1224–1228.
[16] Ouyang, X., Huo, J., Xia, L., Shan, F., Liu, J., Mo, Z., Yan, F., Ding, Z., Yang, Q., Song, B. and Shi, F., 2020. Dual-Sampling Attention Network for Diagnosis of COVID-19 from Community Acquired Pneumonia. IEEE Transactions on Medical Imaging.
[17] Wang, J., Bao, Y., Wen, Y., Lu, H., Luo, H., Xiang, Y., et al. Prior-Attention Residual Learning for More Discriminative COVID-19 Screening in CT Images. *IEEE Transactions on Medical Imaging*. 2020; 39(8), 2572–2583.
[18] Bai, H. X., Wang, R., Xiong, Z., Hsieh, B., Chang, K., Halsey, K., et al. Artificial Intelligence Augmentation of Radiologist Performance in Distinguishing COVID-19 from Pneumonia of Other Origin at Chest CT. *Radiology*. 2020; 296(3).
[19] Ni, Q., Sun, Z. Y., Qi, L., Chen, W., Yang, Y., Wang, L., et al. A deep learning approach to characterize 2019 coronavirus disease (COVID-19) pneumonia in chest CT images. *European Radiology*. 2020; 1–11.
[20] Lessmann, N., Sánchez, C. I., Beenen, L., Boulogne, L. H., Brink, M., Calli, E., et al. Automated Assessment of CO-RADS and Chest CT Severity Scores in Patients with Suspected COVID-19 Using Artificial Intelligence. *Radiology*. 2020; 202439.
[21] Harmon, S. A., Sanford, T. H., Xu, S., Turkbey, E. B., Roth, H., Xu, Z., et al. Artificial intelligence for the detection of COVID-19 pneumonia on chest CT using multinational datasets. *Nature Communications*. 2020; 11(1), 4080.
[22] Zhang, Ran, et al. "Diagnosis of covid-19 pneumonia using chest radiography: Value of artificial intelligence." Radiology (2020): 202944.
[23] Anastasopoulos, C., Weikert, T., Yang, S., Abdulkadir, A., Schmülling, L., Bühler, C., et al. Development and clinical implementation of tailored image analysis tools for COVID-19 in the midst of the pandemic: The synergetic effect of an open, clinically embedded software development platform and machine learning. *European Journal of Radiology*. 2020; 131, 109233.

[24] Zhang, H.-T., Zhang, J.-S., Zhang, H.-H., Nan, Y.-D., Zhao, Y., Fu, E.-Q., et al. Automated detection and quantification of COVID-19 pneumonia: CT imaging analysis by a deep learning-based software. *European Journal of Nuclear Medicine and Molecular Imaging*. 2020; 47(11), 2525–2532.
[25] Zhou, L., Li, Z., Zhou, J., Li, H., Chen, Y., Huang, Y., et al. A Rapid, Accurate and Machine-Agnostic Segmentation and Quantification Method for CT-Based COVID-19 Diagnosis. *IEEE Transactions on Medical Imaging*. 2020; 39(8), 2638–2652.
[26] Blain, M., Kassin, M. T., Varble, N., Wang, X., Xu, Z., Xu, D., et al. Determination of disease severity in COVID-19 patients using deep learning in chest X-ray images. *Diagnostic and Interventional Radiology*. 2020.
[27] Zhang, K., Liu, X., Shen, J., Li, Z., Sang, Y., Wu, X., et al. Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography. *Cell*. 2020; 181(6), 1360.
[28] Soares, Eduardo, et al. "SARS-CoV-2 CT-scan dataset: A large dataset of real patients CT scans for SARS-CoV-2 identification." medRxiv (2020).
[29] Cohen, Joseph Paul, et al. "Covid-19 image data collection: Prospective predictions are the future." arXiv preprint arXiv:2006.11988 (2020).
[30] Born, Jannis, et al. "Accelerating COVID-19 Differential Diagnosis with Explainable Ultrasound Image Analysis." arXiv preprint arXiv:2009.06116 (2020).
[31] G. Pascarella *et al.*, "COVID-19 diagnosis and management: a comprehensive review," *J. Intern. Med.*, vol. 288, no. 2, pp. 192–206, Aug. 2020.
[32] M. Lisboa Bastos *et al.*, "Diagnostic accuracy of serological tests for covid-19: Systematic review and meta-analysis," *BMJ*, vol. 370, p. 2516, Jul. 2020.
[33] Y. W. Tang, J. E. Schmitz, D. H. Persing, and C. W. Stratton, "Laboratory diagnosis of COVID-19: Current issues and challenges," *Journal of Clinical Microbiology*, vol. 58, no. 6. American Society for Microbiology, 01-Jun-2020.
[34] T. Ai *et al.*, "Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases," *Radiology*, p. 200642, 2020.
[35] J. B. Mendel, J. T. Lee, and D. Rosman, "Current Concepts Imaging in COVID-19 and the Challenges for Low and Middle Income Countries The Journal of Global Radiology Imaging findings," *J. Glob. Radiol.*, 2020.
[36] L. Li *et al.*, "Artificial intelligence distinguishes covid-19 from community acquired pneumonia on chest ct," *Radiology*, p. 200905, 2020.
[37] Shiri, Isaac, et al. "Ultra-low-dose chest CT imaging of COVID-19 patients using a deep residual neural network." European radiology (2020): 1-12.
[38] Zhang, Ran, et al. "Diagnosis of covid-19 pneumonia using chest radiography: Value of artificial intelligence." Radiology (2020): 202944.
[39] M. Li et al., "Coronavirus Disease (COVID-19): Spectrum of CT Findings and Temporal Progression of the Disease," Academic Radiology, vol. 27, no. 5. Elsevier USA, pp. 603–608, 01-May-2020.
[40] World Health Organization, "Use of chest imaging in COVID-19: a rapid advice guide, 11 June 2020," 2020.
[41] S. M. H. Tabatabaei, H. Talari, F. Moghaddas, and H. Rajebi, "Computed Tomographic Features and Short-term Prognosis of Coronavirus Disease 2019 (COVID-19) Pneumonia: A Single-Center Study from Kashan, Iran," Radiol. Cardiothorac. Imaging, vol. 2, no. 2, p. e200130, Apr. 2020.
[42] Del Valle, D.M., Kim-Schulze, S., Huang, H.H., Beckmann, N.D., Nirenberg, S., Wang, B., Lavin, Y., Swartz, T.H., Madduri, D., Stock, A. and Marron, T.U., 2020. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature medicine, 26(10), pp.1636-1643.
[43] H. Shi et al., "Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study," Lancet Infect. Dis., vol. 20, no. 4, pp. 425–434, Apr. 2020.
[44] Chaganti, Shikha, et al. "Automated quantification of CT patterns associated with COVID-19 from chest CT." Radiology: Artificial Intelligence 2.4 (2020): e200048.
[45] Tilborghs, Sofie, et al. "Comparative study of deep learning methods for the automatic segmentation of lung, lesion and lesion type in CT scans of COVID-19 patients." arXiv preprint arXiv:2007.15546 (2020).
[46] Wang, Guotai, et al. "A noise-robust framework for automatic segmentation of covid-19 pneumonia lesions from ct images." IEEE Transactions on Medical Imaging 39.8 (2020): 2653-2663.
[47] Xie, Weiyi, et al. "Relational modeling for robust and efficient pulmonary lobe segmentation in CT scans." IEEE transactions on medical imaging 39.8 (2020): 2664-2675.
[48] M. Castillo, "The industry of CT scanning." Am Soc Neuroradiology, 2012.
[49] H. Y. F. Wong et al., "Frequency and Distribution of Chest Radiographic Findings in COVID-19 Positive Patients," Radiology, p. 201160, Mar. 2019.
[50] M. J. Smith, S. A. Hayward, S. M. Innes, and A. Miller, "Point-of-care lung ultrasound in patients with COVID-19--a narrative review," Anaesthesia, 2020.
[51] Akl EA, Blazic I, Yaacoub S, Frija G, Chou R, Appiah JA, Fatehi M, Flor N, Hitti E, Jafri H, Jin ZY, Kauczor HU, Kawooya M, Kazerooni EA, Ko JP, Mahfouz R, Muglia V, Nyabanda R, Sanchez M, Shete PB, Ulla M, Zheng C, van Deventer E, Perez MDR. Use of Chest Imaging in the Diagnosis and Management of COVID-19: A WHO Rapid Advice Guide. Radiology. 2020 Jul 30:203173. doi: 10.1148/radiol.2020203173. Epub ahead of print. PMID: 32729811; PMCID: PMC7393953.

[52] L. Vetrugno et al., “Our Italian experience using lung ultrasound for identification, grading and serial follow-up of severity of lung involvement for management of patients with COVID-19,” *Echocardiography*, vol. 37, no. 4. Blackwell Publishing Inc., 2020.
[53] E. M. S.-P. J.R. Pare, I. Camelo, K.C. Mayo, M.M. Leo, J.N. Dugas, K.P. Nelson, W.E. Baker, F. Shareef, R.N. Mitchell, M. Patrica, “Point-of-care Lung Ultrasound Is More Sensitive than Chest Radiograph for Evaluation of COVID-19,” *West. J. Emerg. Med. Integr. Emerg. Care with Popul. Heal*., 2020
[54] Lieveld, A. W. E., et al. "Diagnosing COVID-19 pneumonia in a pandemic setting: Lung Ultrasound versus CT (LUVCT) A multi-centre, prospective, observational study." *ERJ Open Research* (2020).
[55] Y. Tung-Chen, M. Martí de Gracia, A. Díez-Tascón, R. Alonso-González, S. Agudo-Fernández, M. L. Parra-Gordo, S. Ossaba-Vélez, P. Rodríguez-Fuertes, and R. Llamas-Fuentes, “Correlation between Chest Computed Tomography and Lung Ultrasonography in Patients with Coronavirus Disease 2019 (COVID-19),” *Ultrasound in Medicine and Biology*, vol. 46, pp. 2918–2926, nov 2020.
[56] Y. Tung-Chen et al., “Correlation between Chest Computed Tomography and Lung Ultrasonography in Patients with Coronavirus Disease 2019 (COVID-19),” *Ultrasound Med. Biol*., vol. 0, no. 0, 2020
[57] D. Buonsenso, D. Pata, and A. Chiaretti, “COVID-19 outbreak: less stethoscope, more ultrasound,” *Lancet Respir. Med.*, 2020.
[58] J. C. H. Cheung and K. N. Lam, “POCUS in COVID-19: pearls and pitfalls,” The Lancet Respiratory Medicine, vol. 8, no. 5. Lancet Publishing Group, p. e34, 01-May-2020
[59] McKinney, Scott Mayer, et al. "International evaluation of an AI system for breast cancer screening." Nature 577.7788 (2020): 89-94.
[60] Haibe-Kains, Benjamin, et al. "Transparency and reproducibility in artificial intelligence." *Nature* 586.7829 (2020): E14-E16.
[61] Yan, Li, et al. "An interpretable mortality prediction model for COVID-19 patients." *Nature Machine Intelligence* (2020): 1-6.
[62] Barish, Matthew, et al. "External validation demonstrates limited clinical utility of the interpretable mortality prediction model for patients with COVID-19." *Nature Machine Intelligence* (2020): 1-3.
[63] Quanjel, Marian JR, et al. "Replication of a mortality prediction model in Dutch patients with COVID-19." *Nature Machine Intelligence* (2020): 1-2.
[64] Dupuis, C., et al. "Limited applicability of a COVID-19 specific mortality prediction rule to the intensive care setting." *Nature Machine Intelligence* (2020): 1-3.

# List of Tables

*Table 1. Mature AI for MI papers, Q1-Q3 2020. These 13 papers were ranked with a maturity level of "high" in the meta-analysis.*

| Paper Title | First Author | Task | Modality |
|---|---|---|---|
| Artificial intelligence–enabled rapid diagnosis of patients with COVID-19 | Mei[15] | Diagnosis | CT |
| Dual-Sampling Attention Network for Diagnosis of COVID-19 from Community Acquired Pneumonia | Ouyang[16] | Diagnosis | CT |
| Prior-Attention Residual Learning for More Discriminative COVID-19 Screening in CT Images | Wang[17] | Diagnosis | CT |
| Artificial Intelligence Augmentation of Radiologist Performance in Distinguishing COVID-19 from Pneumonia of Other Origin at Chest CT | Bai[18] | Diagnosis | CT |
| A deep learning approach to characterize 2019 coronavirus disease (COVID-19) pneumonia in chest CT images | Ni[19] | Diagnosis | CT |
| Automated Assessment of CO-RADS and Chest CT Severity Scores in Patients with Suspected COVID-19 Using Artificial Intelligence | Lessmann[20] | Diagnosis | CT |
| Artificial intelligence for the detection of COVID-19 pneumonia on chest CT using multinational datasets | Harmon[21] | Diagnosis | CT |
| Diagnosis of COVID-19 Pneumonia Using Chest Radiography: Value of Artificial Intelligence | Zhang[22] | Diagnosis | CXR |
| Development and clinical implementation of tailored image analysis tools for COVID-19 in the midst of the pandemic: The synergetic effect of an open, clinically embedded software development platform and machine learning | Anastasopoulos[23] | Severity Assessment | CT |
| Automated detection and quantification of COVID-19 pneumonia: CT imaging analysis by a deep learning-based software | Zhang[24] | Severity Assessment | CT |
| A Rapid, Accurate and Machine-Agnostic Segmentation and Quantification Method for CT-Based COVID-19 Diagnosis | Zhou[25] | Severity Assessment | CT |
| Determination of disease severity in COVID-19 patients using deep learning in chest X-ray images | Blain[26] | Severity Assessment | CXR |
| Clinically Applicable AI System for Accurate Diagnosis, Quantitative Measurements, and Prognosis of COVID-19 Pneumonia Using Computed Tomography | Zhang[27] | Prognosis | CT |

*Table 2. Differences between the imaging modalities.*

| | CT | CXR | LUS |
|---|---|---|---|
| Benefit | High sensitivity, high specificity | Fast, broadly available | Mobile, radiation-free, broadly available |
| Drawback | Patient transportation<br>Low availability<br>Radiation dose<br>Increased workload for disinfection | Low sensitivity<br>Non-specific<br>Large volume of radiographs leads to increased workload. | User dependent<br>Non-specific<br>Long acquisition time<br>Requires patient interaction |
| Clinical Role | Diagnose additional complications<br>Rule out additional etiologies of symptoms (effusions, bacterial pneumonia) | Initial diagnosis<br>Monitoring clinical progression<br>Detection of complications | Triage<br>Point-of-care monitoring for specific tasks |

# List of Figures




***Fig. 1. PRISMA flowchart illustrating the study selection used in the systematic review and meta-analysis.*** *Publication keyword searches on PubMed, arXiv, biorXiv and medRxiv for Q1-Q3 of 2020 were performed using two parallel streams. After duplicate matches were removed, titles were screened manually and a selection of 338 relevant manuscripts were chosen for manual review.*




***Fig. 2*** *AI for medical imaging is received growing attention in 2020, at least partially due to the COVID-19 pandemic. Automatic keyword searches on PubMed and preprint servers revealed 2563 papers on AI and MI in 2019 (left), while Q1-Q3 of 2020 have seen already 3597 such papers (right).*




***Fig. 3: Number of papers per keyword and platform.*** *Left: Paper counts using AI on breast or lung imaging. Right: Paper counts comparing the usage of AI on lung imaging modalities. The lightly shaded bars exclude COVID-19 related papers, which shows the continuity of publications without COVID-19. For each keyword, multiple synonyms were used (for details see appendix Table A1).*




***Fig. 4: Imaging modality comparison during the COVID-19 pandemic.*** *CT takes the lion's share of clinical papers about lung imaging of COVID-19 (left). The AI community (right) instead published disproportionally more papers on CXR compared to clinicians, whereas CT and Ultrasound are vastly underrepresented. Multimodal papers used more than one imaging modality.*




***Fig. 5: Distribution of manually reviewed papers on AI and medical imaging during the COVID-19 pandemic****. Relative proportions for primary performed task (left), quality (middle) and data origin (right) are given.*